Search
Close this search box.
Search
Close this search box.

Advanced Therapeutics & Disease Modification

Epilepsy is a diverse condition, with many underlying causes, seizure types and responses to treatments, all of which can vary greatly among individuals.

This individual variability poses a significant challenge in epilepsy management, but also presents an opportunity for personalised treatment approaches in genetics, pharmacology and neuroimaging.

Finding treatments for drug-resistant epilepsy and treatments that effectively control seizures while minimising side effects, is vital for people with epilepsy. By understanding the intricate causes of epilepsy and the pathways involved in seizure generation, researchers can design medications that specifically target these pathways in a way that works for all people with epilepsy.

Our research priorities

  • Develop a pipeline to identify and test new treatments for epilepsy that will not only stop seizures, but prevent seizures occurring in the first place. The pipeline will include genomic discovery, further discovery and mechanistic work in animal and human cell tissue models and clinical trials.
  • Identify mechanisms by which the human brain becomes susceptible to unprovoked seizures that are ‘druggable’.
  • Identify treatment for exemplar rare genetic epilepsies, leveraging international collaborations and consortia to which we are already key partners.
  • Identify ‘druggable’ pathways in common focal and generalised epilepsies.
  • Develop screening algorithms including AI to prioritise candidate treatments.
  • Clinical trials programme (early and later phase) in collaboration with industry and UKRI.

Advanced Therapeutics & Disease Modification theme leads

Clinical Co-Lead: Professor Michael Johnson, Imperial College London
Basic Science Co-Lead: Professor Gabriele Lignani, UCL Queen Square Institute of Neurology
Early Career Lead: Dr Gareth Morris, University of Manchester/UCL

The Advanced Therapeutics & Disease Modification theme leads will be supported by a task force of preeminent UK scientists and clinicians. The team is driving a research programme to feed into an overall roadmap for research into epilepsy in order to secure largescale investment.

Advanced Therapeutics & Disease Modification on The Hub

Join The Hub – the online discussion portal for researchers working in the field of epilepsy and associated conditions – to find and share networking and collaboration opportunities, as well as workshops and events. If you would like to be involved in the task force group for the programme, you can find more information on The Hub here.